Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Topics: Population, Cancer, Breast cancer, Medicine, Metastatic breast cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: Despite preselecting patients for targeted treatment, the open-label, two-stage, Phase II study BASALT-1 did not meet its primary objective during Stage 1 and Combinations of PI3K inhibitors with other agents may demonstrate greater efficacy than monotherapy.
126 citations
TL;DR: NIVO + IPI was shown to improve overall survival (OS) and durability of response vs chemo in 1L advanced NSCLC in CheckMate 227 Part 1, regardless of PD-L1 expression, and this work hypothesizes that adding IPI to NIVO may improve survival and durability.
Abstract: 9501Background: NIVO + IPI was shown to improve overall survival (OS) and durability of response vs chemo in 1L advanced NSCLC in CheckMate 227 Part 1, regardless of PD-L1 expression. We hypothesiz...
126 citations
Katholieke Universiteit Leuven1, Tel Aviv Sourasky Medical Center2, Vanderbilt University Medical Center3, The Royal Marsden NHS Foundation Trust4, Institut Gustave Roussy5, University of Pennsylvania6, University of Oxford7, University of Toronto8, Martin Luther University of Halle-Wittenberg9, Hebron University10, Leiden University Medical Center11
TL;DR: There is now robust evidence in favour of systemic therapy with sorafenib in patients with advanced HCC with preserved liver function, and those involved in the care for patients with HCC should be encouraged to participate in well-designed clinical trials, to increase evidence-based knowledge and to make further progress.
126 citations
Princess Margaret Cancer Centre1, Memorial Sloan Kettering Cancer Center2, University of Sydney3, Hebron University4, Samsung Medical Center5, Yale University6, University of Pennsylvania7, Vanderbilt University8, University of California, San Francisco9, Emory University10, Merck & Co.11, University of California, Los Angeles12
TL;DR: Pembrolizumab provides durable response and long-term effects on overall survival, with tolerable safety, for treatment naive and previously treated patients with advanced non-small-cell lung cancer expressing PD-L1.
125 citations
King's College London1, University College London2, Queen Mary University of London3, Hebron University4, Institut Gustave Roussy5, Icahn School of Medicine at Mount Sinai6, Samsung Medical Center7, University of Milan8, Harvard University9, Seoul National University Hospital10, Huntsman Cancer Institute11, National Taiwan University12, The Chinese University of Hong Kong13, University of Miami14, National Cheng Kung University15, University of Barcelona16, Hoffmann-La Roche17, University of Ulsan18
TL;DR: Subbiah et al. as mentioned in this paper evaluated fisogatinib (BLU-554), a highly potent and selective oral FGFR4 inhibitor, in a phase I dose-escalation/dose-expansion study in advanced hepatocellular carcinoma (HCC) using FGF19 expression measured by IHC as a biomarker for pathway activation.
Abstract: Outcomes for patients with advanced hepatocellular carcinoma (HCC) remain poor despite recent progress in drug development. Emerging data implicate FGF19 as a potential HCC driver, suggesting its receptor, FGFR4, as a novel therapeutic target. We evaluated fisogatinib (BLU-554), a highly potent and selective oral FGFR4 inhibitor, in a phase I dose-escalation/dose-expansion study in advanced HCC using FGF19 expression measured by IHC as a biomarker for pathway activation. For dose escalation, 25 patients received 140 to 900 mg fisogatinib once daily; the maximum tolerated dose (600 mg once daily) was expanded in 81 patients. Fisogatinib was well tolerated; most adverse events were manageable, grade 1/2 gastrointestinal events, primarily diarrhea, nausea, and vomiting. Across doses, the overall response rate was 17% in FGF19-positive patients [median duration of response: 5.3 months (95% CI, 3.7-not reached)] and 0% in FGF19-negative patients. These results validate FGFR4 as a targetable driver in FGF19-positive advanced HCC. SIGNIFICANCE: Fisogatinib elicited clinical responses in patients with tumor FGF19 overexpression in advanced HCC. These results validate the oncogenic driver role of the FGFR4 pathway in HCC and the use of FGF19 as a biomarker for patient selection.See related commentary by Subbiah and Pal, p. 1646.This article is highlighted in the In This Issue feature, p. 1631.
125 citations
Authors
Showing all 2723 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| José Baselga | 156 | 707 | 122498 |
| M. I. Martínez | 134 | 1251 | 79885 |
| Josep Tabernero | 111 | 803 | 68982 |
| Jordi Rello | 103 | 694 | 35994 |
| Xavier Montalban | 95 | 762 | 52842 |
| James M. Downey | 91 | 381 | 29506 |
| Enriqueta Felip | 83 | 622 | 53364 |
| Joaquim Bellmunt | 82 | 660 | 41472 |
| Joan Montaner | 80 | 489 | 22413 |
| Marc Miravitlles | 76 | 651 | 25671 |
| David H. Salat | 75 | 241 | 36779 |
| Eduard Gratacós | 75 | 531 | 20178 |
| Alex Rovira | 74 | 356 | 19586 |
| Ramon Bataller | 72 | 283 | 19316 |
| Maria Buti | 71 | 493 | 26596 |